DAVID B SANFORD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology HOUSTON, TX NPI 1629039342
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology TX Apellis Pharmaceuticals, Inc. All categories
General Payments — all program years on this page
$2,577.89
- Category: General Payments
- Program years: PY2018–2024
- Record count: 133
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $792.56 across 34 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $717.00 | 32 |
| Education | $75.56 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | $75.56 | 2 |
| Daiichi Sankyo Inc. | $55.65 | 2 |
| SpringWorks Therapeutics, Inc. | $51.89 | 3 |
| Janssen Biotech, Inc. | $45.41 | 2 |
| PFIZER INC. | $44.86 | 2 |
| Incyte Corporation | $40.80 | 2 |
| BeiGene USA, Inc. | $38.13 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $34.63 | 2 |
| Kite Pharma, Inc. | $34.51 | 1 |
| Rigel Pharmaceuticals, Inc. | $31.60 | 1 |
| PharmaEssentia USA Corporation | $30.50 | 1 |
| Gilead Sciences, Inc. | $28.45 | 1 |
| GlaxoSmithKline, LLC. | $28.28 | 1 |
| TAIHO ONCOLOGY, INC. | $27.83 | 1 |
| Acerta Pharma LLC | $25.25 | 1 |
| SECURA BIO, INC. | $23.80 | 1 |
| Stemline Therapeutics Inc. | $23.53 | 1 |
| Exelixis Inc. | $22.82 | 1 |
| Merck Sharp & Dohme Corporation | $21.33 | 1 |
| Astellas Pharma US Inc | $19.38 | 1 |
| E.R. Squibb & Sons, L.L.C. | $19.06 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $18.93 | 1 |
| Sirtex Medical Inc | $18.53 | 1 |
| Celgene Corporation | $16.11 | 1 |
| Tempus AI, Inc | $15.72 | 1 |
By program year
Records — PY2024 (34)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.